Here is a direct lift from the study: "The present study (a cross-sectional study) included 30 patients group II; 15 patients with controlled DM (group IIA) and 15 patients with uncontrolled DM (group IIB) admitted to chest and internal medcine departments, Menoufiya University hospitals in the period from February 2013 to August 2013. We also included 15 healthy non diabetic subjects who volunteered as a control group."
Let me put this article to rest. The study is not valid because there are not enough individuals in the sample to extract anything of statistical significance. In fact, they used a statistical package that is geared to the social sciences: "The data collected were tabulated & analyzed by SPSS (statistical package for the social science software, statistical package version 11.)" They looked at 15 diabetics with good control, 15 diabetics with poor control vs. 15 non-diabetics. Generally you need a sample size of 100 in each cell to draw any valid conclusions. Also, all of the diabetics had been admitted to the hospital with chest pains. Um, aren't you stacking the deck when when your subjects had been admitted to the hospital with chest pains? This whole thing is pure hogwash.
The 25 thumbs down is very telling. I don't recall having seen such a high number on this board before on a post by a long.
I know this may sound dumb but I couldn't figure out how to access an email address with factspls on it. I have a yahoo email address with my real name on it. Any advice?
Seer could you expand on the tinnitus? I recently came down with it and have been shocked that there are no known cures. It is brutal. Had to give up my Eagles tickets at MSG because of it. ;)
Selling all of my longs and replacing with ultra shorts of the Dow, S&P, and Nasdaq. Thanks for the heads up and detailed analysis.
Then the insulin in the cooler will be free since it was already expensed. That is, of course, assuming Sanofi chooses to use it. Surely you know that opc.
For a quick pick-me-up, just watch Afrezzauser's testimony at AdCom. If I remember correctly he is the first speaker - name is Sam.
Whatever it is, I find it almost impossible to believe that it would be anything that would jeopardize a Q1 2015 intro. FDA approval falls into the realm of jeopardizing a Q1 intro so I just don't see it.
They should check out MNKD. They'd likely find hundreds of buy and sells on a daily basis instigated by a high number of hedge funds.
What, and give everything away to competitors? Have you ever worked on a new product launch? Or in a large corporation? Why do you think companies like Apple are so secretive with their new product pipeline? Kevin, I think you make some great contributions to this board but you are way off base on this one.
I would guess that they have filled the lead with an experienced exec from within Sanofi. At least that is what I would hope and expect.